Proactive Investors - Run By Investors For Investors

LeanLife issues stock options

The company said it had granted incentive stock options to certain officers, directors and consultants
omega 3
Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives

LeanLife Health Inc (CSE:LLP) said Thursday that it has granted stock options to certain officers, directors and consultants, pursuant to its 10% rolling stock option plan. 

The company said certain officers, directors and consultants will be entitled to purchase a total of 4,900,000 common shares of the company at an exercise price of C$0.05 per share for a three-year-term.

READ: LeanLife Health taps Chris Nichols as operations advisor

The company said the term will expire on February 7, 2022.

Lean Life Health develops omega-3 products which can be formulated as liquids, emulsions or powders and used as food additives

Shares of LeanLife were up 11.1% at C$0.05 on Thursday. 

View full LLP profile View Profile

LeanLife Health Timeline

Newswire
February 07 2019

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1534940807_rsz_shutterstock_130327115.jpg
August 22 2018
The group's products are extracted from flaxseeds, a plentiful and non-animal source of omega-3.
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use